These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27036325)

  • 21. Investigating drug repositioning opportunities in FDA drug labels through topic modeling.
    Bisgin H; Liu Z; Kelly R; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2012; 13 Suppl 15(Suppl 15):S6. PubMed ID: 23046522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Internet and drug safety: what are the implications for pharmacovigilance?
    Cobert B; Silvey J
    Drug Saf; 1999 Feb; 20(2):95-107. PubMed ID: 10082068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Alatawi YM; Hansen RA
    Expert Opin Drug Saf; 2017 Jul; 16(7):761-767. PubMed ID: 28447485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database.
    Mazhar F; Battini V; Gringeri M; Pozzi M; Mosini G; Marran AMN; Akram S; van Manen RP; Radice S; Clementi E; Carnovale C
    Expert Opin Biol Ther; 2021 Sep; 21(9):1281-1290. PubMed ID: 34191656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
    Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
    Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mining Drugs and Indications for Suicide-Related Adverse Events.
    Ding T; Chen ES
    AMIA Annu Symp Proc; 2019; 2019():1011-1020. PubMed ID: 32308898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Digital drug safety surveillance: monitoring pharmaceutical products in twitter.
    Freifeld CC; Brownstein JS; Menone CM; Bao W; Filice R; Kass-Hout T; Dasgupta N
    Drug Saf; 2014 May; 37(5):343-50. PubMed ID: 24777653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
    Teng C; Baus C; Wilson JP; Frei CR
    Int J Med Sci; 2019; 16(11):1504-1509. PubMed ID: 31673242
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Interactive User Interface for Drug Labeling to Improve Readability and Decision-Making.
    Abedtash H; Duke JD
    AMIA Annu Symp Proc; 2015; 2015():278-86. PubMed ID: 26958158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease.
    Chrétien B; Jourdan JP; Davis A; Fedrizzi S; Bureau R; Sassier M; Rochais C; Alexandre J; Lelong-Boulouard V; Dolladille C; Dallemagne P
    Br J Clin Pharmacol; 2021 Jul; 87(7):2830-2837. PubMed ID: 33274491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leveraging MEDLINE indexing for pharmacovigilance - Inherent limitations and mitigation strategies.
    Winnenburg R; Sorbello A; Ripple A; Harpaz R; Tonning J; Szarfman A; Francis H; Bodenreider O
    J Biomed Inform; 2015 Oct; 57():425-35. PubMed ID: 26342964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials.
    Borrelli EP; McGladrigan CG
    J Oncol Pharm Pract; 2021 Jun; 27(4):887-896. PubMed ID: 32686617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.